Loading
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (2 ops.)
Latest filing published 04 Mar 2022 for Aurinia Pharmaceuticals Inc.. Read the official filing
Filing timeline
BuySaleRobert Bindert Huizinga
Insider track record
Disclosed buys
0
Disclosed sells
2
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Robert Bindert Huizinga: trading record in brief
Robert Bindert Huizinga (senior executive) discloses dealings in Aurinia Pharmaceuticals Inc. to SEC (Form 4). Between 11 May 2021 and 2 March 2022, the trades on record add up to 6 filings.
No open-market purchase appears, only 2 sales worth €161k. Other entries cover 1 share grant and 3 option exercises.
The record was last updated on 4 March 2022 with a share grant in Aurinia Pharmaceuticals Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. For comparison, the SEC allows two business days to file a Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Robert Bindert Huizinga
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations6 total
8,500 shares0Common StockSEC:0001628280-22-005118:0
95,000 shares@ US$3.2046.9% of flowCommon StockSEC:0001628280-21-020527:0
16,000 shares@ US$2.636.4% of flowCommon StockSEC:0001628280-21-019051:0
5,000 shares@ US$19.8315.0% of flowCommon StockSEC:0001628280-21-018595:0
5,000 shares@ US$18.3013.8% of flowCommon StockSEC:0001628280-21-018218:0
40,000 shares@ US$3.0217.8% of flowCommon StockSEC:0001628280-21-009847:0
6 of 6 declarations
